Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastasis
Interventions: DRUG: Dasatinib|DRUG: Dasatinib 100 mg
Sponsor: Bristol-Myers Squibb